Does Biogen Stock Deserve More Credit for Q1 Earnings?

By Chris Lange Published Apr 22, 11:24AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Does Biogen Stock Deserve More Credit for Q1 Earnings? — © biogen.com

When Biogen Inc. (NASDAQ: BIIB | BIIB Price Prediction) reported its first-quarter financial results before the markets opened on Wednesday, the firm said that it had $9.14 in earnings per share (EPS) and $3.53 billion in revenue. Analysts were calling for $7.73 in EPS and revenue $3.41 billion. The same period of last year reportedly had EPS of $6.98 on $3.39 billion in revenue.

Concerning the COVID-19 pandemic, Biogen estimates that its first-quarter product revenues benefitted by approximately $100 million, attributed to accelerated sales as a result, primarily in Europe.

[in-text-ad]

In terms of its segments, the company reported as follows:

Multiple sclerosis (MS) revenues, including $162 million in royalties on the sales of Ocrevus, increased 9% versus the prior year to $2,280 million.

Spinraza revenues increased 9% versus the prior year to $565 million.

Biosimilars revenues increased 25% versus the prior year to $219 million.

Other revenues decreased 63% versus the prior year to $109 million primarily due to the sale of approximately $200 million of hemophilia inventory to Bioverativ in the first quarter of 2019.

[nativounit]

At the end of the quarter, Biogen had cash, cash equivalents and marketable securities totaling approximately $4.83 billion and approximately $5.96 billion in notes payable.

Biogen did not issue guidance for the second quarter. However, analysts are calling for $8.28 in EPS and $3.54 billion in revenue. Looking ahead to the full year, analysts are forecasting $32.29 in EPS and $14.06 billion in revenue.

Michel Vounatsos, Biogen’s CEO, commented:

The COVID-19 pandemic has created a challenging situation for people and companies throughout the world, and Biogen personally felt the painful impact of this global crisis. During these challenging and unprecedented times, Biogen has continued to deliver on its mission and purpose. We have continued to operate our business and deliver our therapies to patients across the world and are especially grateful to our dedicated employees as we continue to execute on our strategy.

Biogen stock traded down about 11% to $293.77 on Wednesday, in a 52-week range of $215.78 to $374.99. The consensus price target is $331.69.

[recirclink id=683567][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.